{"disease":{"id":"nonproliferative-diabetic-retinopathy","name":"nonproliferative diabetic retinopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02718326","title":"Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03197870","title":"The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05383209","title":"Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03863535","title":"PRP vs PRP+IVC for Severe nPDR","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Ruijin Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}